Contact
Please use this form to send email to PR contact of this press release:
Sethera Therapeutics’ Polymacrocyclic Peptide Platform Selected for CDMRP-Supported Mutant p53 Breast Cancer Program
TO:
Karsten Eastman
Sethera Therapeutics, Inc.
+1 8018504367